Celcuity Inc. Advances SEC Compliance and Capital Markets Goals

Celcuity Inc., a biotechnology company focused on developing innovative therapies for cancer patients, asked Faegre Drinker to provide comprehensive support on Securities and Exchange Commission (SEC) compliance and capital markets transactions. Faegre Drinker worked closely with the company to review and advise on annual and quarterly SEC filings, including Form 10-K and Form 10-Q filings, helping ensure disclosures met regulatory requirements and accurately reflected the company’s operations. The team also assisted Celcuity Inc. in preparing and filing Form 8-Ks for material events, including new executive compensation arrangements and loan agreements.

For the company’s officers and directors, Faegre Drinker prepared Section 16 filings, including Forms 3 and 4, to facilitate proper insider transaction reporting. Additionally, the firm managed Schedule 13G filings for significant stockholders, evaluating reporting thresholds and coordinating submissions as needed. Most recently, Faegre Drinker supported Celcuity Inc. in executing a concurrent convertible notes and common stock offering, raising over $250 million to accelerate the company’s clinical development and commercialization objectives. This partnership provided Celcuity Inc. with the legal guidance and strategic counsel necessary to achieve its business goals and maintain compliance with federal securities laws.